July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug ...

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising ...

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic ...

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

July 15 (Reuters) - Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weight ...

Vivani says its implant delivers medication steadily over long periods of time.

Vivani Medical (NASDAQ:VANI) said it is preparing to begin human testing of its semaglutide implant in August and highlighted ...

The stock is down, but it isn't out yet.

Lately, it has become almost impossible to have a conversation about weight loss without the name semaglutide, more commonly ...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

One injection a week instead of one every day. Danish drugmaker Novo Nordisk has launched Awiqli, or insulin icodec, in India-the world's first once-weekly bas ...

The interim analysis included 426 participants aged one year and above.